Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?
Paul R. Walker · 2026
Read Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes? by Paul R. Walker (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13608606.txt.
Description
Paul Walker asks whether blood tests for leftover cancer DNA should steer lung cancer care yet. Molecular residual disease testing hunts circulating tumor DNA after surgery for non-small cell lung cancer. The hope is to catch return early and aim extra treatment. Assays keep getting more sensitive. His 2026 commentary grants the technology its pace, then presses the outcome question. No proof yet shows patients live longer because of the tests.
Tumor biology clouds the picture: patchy tumors shed unevenly, and clones evolve. A fifth of patients classed negative at the landmark still relapse. Extra treatment helps some test-negative patients anyway. Positive turns can precede scans by months with no proven early move. Walker urges trials before the test becomes a guide.
Catalog record
| CREATOR | Paul R. Walker |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |